A compilation of antimicrobial susceptibility data from a network of 13 Lebanese hospitals reflecting the national situation during 2015-2016.
Anti-Bacterial Agents
/ pharmacology
Carbapenems
/ pharmacology
Cephalosporins
/ pharmacology
Drug Resistance, Bacterial
Enterobacteriaceae
/ classification
Europe, Eastern
Gram-Negative Bacteria
/ classification
Gram-Positive Bacteria
/ classification
Hospitals
Humans
Lebanon
/ epidemiology
Microbial Sensitivity Tests
Population Surveillance
Retrospective Studies
Antimicrobial susceptibility
Antimicrobial susceptibility testing
Lebanon
Resistance
Surveillance
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
12
2018
accepted:
01
02
2019
entrez:
5
3
2019
pubmed:
5
3
2019
medline:
21
4
2020
Statut:
epublish
Résumé
There is a lack of official national antimicrobial resistance (AMR) data in Lebanon. Individual hospitals generate their own antibiotic susceptibility data in the form of yearly pamphlets. In this study, antibiotic susceptibility data from 13 hospitals distributed across different governorates of Lebanon were collected to conduct a compilation-based surveillance of AMR in Lebanon for the years 2015-2016. The findings were compared with those of a previous nationwide study in this country conducted between 2011 and 2013 as well as with similar data obtained from the 2015 and 2016 European surveillance reports of AMR. To provide a clear presentation of the AMR situation, mean percent susceptibility of different antibiotic-microbe combinations was calculated. During 2015-2016, the percent susceptibility of This study highlights the need to establish a robust national AMR surveillance system that enables data from Lebanon to be included in global AMR maps.
Sections du résumé
Background
There is a lack of official national antimicrobial resistance (AMR) data in Lebanon. Individual hospitals generate their own antibiotic susceptibility data in the form of yearly pamphlets.
Methods
In this study, antibiotic susceptibility data from 13 hospitals distributed across different governorates of Lebanon were collected to conduct a compilation-based surveillance of AMR in Lebanon for the years 2015-2016. The findings were compared with those of a previous nationwide study in this country conducted between 2011 and 2013 as well as with similar data obtained from the 2015 and 2016 European surveillance reports of AMR. To provide a clear presentation of the AMR situation, mean percent susceptibility of different antibiotic-microbe combinations was calculated.
Results
During 2015-2016, the percent susceptibility of
Conclusion
This study highlights the need to establish a robust national AMR surveillance system that enables data from Lebanon to be included in global AMR maps.
Identifiants
pubmed: 30828445
doi: 10.1186/s13756-019-0487-5
pii: 487
pmc: PMC6381724
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
Cephalosporins
0
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
41Déclaration de conflit d'intérêts
This study is based on institutional antimicrobial susceptibility testing (AST) yearly reports/pamphlets generated and distributed by clinical microbiology laboratories. This information is publically available. The institutional review board (IRB) Committee of one of the participating hospitals, Makassed General Hospital, Beirut, Lebanon, granted this study ethical approval. All data were purely based on microorganisms, and no patient data were included; hence, the IRB waived the requirement of informed consent from patients.Not applicable.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Références
J Hosp Infect. 2018 Dec;100(4):378-385
pubmed: 29906490
BMJ Open. 2017 Jan 23;7(1):e012520
pubmed: 28115331
Clin Infect Dis. 2011 Jul 15;53(2):177-84
pubmed: 21690626
J Infect Public Health. 2015 Jan-Feb;8(1):37-46
pubmed: 25139454
J Infect Dev Ctries. 2018 Mar 31;12(3):164-170
pubmed: 31829991
Am J Infect Control. 2014 Feb;42(2):160-3
pubmed: 24360641
Euro Surveill. 2018 May;23(21):
pubmed: 29845929
J Med Liban. 2012 Jul-Sep;60(3):125-35
pubmed: 23198452
Lancet Infect Dis. 2018 Dec;18(12):e379-e394
pubmed: 30292478
Infection. 2009 Oct;37(5):432-7
pubmed: 19499184
Euro Surveill. 2015 Jul 09;20(27):
pubmed: 26212064
Microb Drug Resist. 2018 Mar;24(2):166-174
pubmed: 28650688
Clin Microbiol Infect. 2004 Apr;10(4):349-83
pubmed: 15059129
Int J Infect Dis. 2016 Nov;52:29-36
pubmed: 27663910
Front Microbiol. 2016 Nov 23;7:1881
pubmed: 27933044
J Med Liban. 2014 Apr-Jun;62(2):107-12
pubmed: 25011373
J Infect Public Health. 2016 Sep-Oct;9(5):618-25
pubmed: 26806876
Infect Drug Resist. 2017 Dec 22;11:17-28
pubmed: 29317840
Int J Infect Dis. 2016 May;46:64-70
pubmed: 26996458
Microb Drug Resist. 2017 Sep;23(6):733-743
pubmed: 28080212
Int J Public Health. 2014 Apr;59(2):319-27
pubmed: 23942698
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
J Infect Public Health. 2018 May - Jun;11(3):405-411
pubmed: 28970096
Int J Antimicrob Agents. 2016 May;47(5):415-6
pubmed: 27155945
Front Cell Infect Microbiol. 2015 Feb 12;5:11
pubmed: 25729741
Infect Ecol Epidemiol. 2015 Jun 24;5:27094
pubmed: 26112266
Front Microbiol. 2018 Mar 23;9:550
pubmed: 29628921